Christel Franchet
Domain Therapeutics (France) · 25 works · 270 citations · h-index 3
Top works
- Small Neutralizing Molecules to Inhibit Actions of the Chemokine CXCL12
- Identification and pharmacological properties of E339–3D6, the first nonpeptidic apelin receptor agonist
- Chemical Switch of a Metabotropic Glutamate Receptor 2 Silent Allosteric Modulator into Dual Metabotropic Glutamate Receptor 2/3 Negative/Positive Allosteric Modulators
- Abstract 312: Comprehensive characterization of DT-7012, a differentiated CCR8-depleting antibody for the treatment of solid tumors
- Discovery of DT-9081, a Potent and Orally Bioavailable Small Molecule Antagonist of the EP4 Receptor for the Treatment of Solid Cancers
- GPCR Binding Technologies: An Overview
- Discovery of BI-9508, a Brain-Penetrant GPR88-Receptor-Agonist Tool Compound for In Vivo Mouse Studies
- Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy
- Identification and Characterization of E339-3D6, the First Nonpeptidic Apelin Receptor Agonist XAVIER ITURRIOZ
- Abstract 6308: Development of a pharmacological platform to study in real time immune checkpoints signaling pathways: validation with therapeutic mAbs and small molecules
- Abstract 2946: Depleting hCCR8 mAb Therapy #1: Characterization of a broad collection of anti-hCCR8 mAbs
- 1324 Characterization of DT-7012, a highly differentiated anti-CCR8 mAb clinical candidate
- Abstract 4356: Comprehensive characterization of DT-7012, a highly differentiated anti-CCR8 depleting antibody
- OP0236 RELEVANCE OF BIASED PAR2 INHIBITORS IN REDUCING INFLAMMATION AND CARTILAGE DEGRADATION IN IN VITRO AND IN VIVO MODELS OF RHEUMATOID ARTHRITIS
- Abstract 2945: Depleting hCCR8 mAb Therapy #2: Selection of candidates for the development of innovative depleting anti CCR8 therapeutic antibodies to control the immunosuppressive tumor microenvironment
- Abstract LB123: A high value pharmacological platform dedicated to the real time study of stimulatory immune checkpoint signaling pathways
- CCDC 2361119: Experimental Crystal Structure Determination
- Abstract 6157: PAR2 inhibitors reduce resistance to immunotherapy against cancer
- Abstract 6697: DT095895, a selective EP4 receptor antagonist with monotherapy efficacy in syngeneic mouse model(s) and best-in-class properties
- Abstract 4961: Novel biased PAR2 inhibitors with best-in-class properties reduce resistance to both chemotherapy and immunotherapy in oncology models